Indo-European Consortium for Next Generation Influenza Vaccine Innovation

Informations projet

INCENTIVE

N° de convention de subvention: 874866

DOI

10.3030/874866

Projet clôturé

Date de signature de la CE 13 Decembre 2019

Date de début 1 Août 2020

Date de fin 31 Janvier 2026

Financé au titre de

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coût total

€ 19 965 992,50

Contribution de l’UE

€ 9 974 293,75

Coordonné par

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
Germany

CORDIS fournit des liens vers les livrables publics et les publications des projets HORIZON.

Les liens vers les livrables et les publications des projets du 7e PC, ainsi que les liens vers certains types de résultats spécifiques tels que les jeux de données et les logiciels, sont récupérés dynamiquement sur OpenAIRE .

Livrables

Documents, reports (4)

INCENTIVE-QIV-1,2,3 (EU) and QIV-1 (India): Study results posted in the study registry

Safety and preliminary immunogenicity results posted on the study registry. Timelines if/when final posting of results is scheduled after end of funding period will be included.

INCENTIVE-QIV: Registration of the clinical trial in the trial registry

Study registered at a WHO or ICMJapproved registry

Development and annual update of INCENTIVE dissemination and exploitation plan delivered

Plan and annual update on dissemination activities and IP exploitation.

A blueprint for rolling out stratified influenza vaccination programs, in order to optimize / maximize efficiency and effectiveness taking into account acceptability, affordability and accessibility issues

Development of blueprint for the rollout of stratified influenza vaccination program.

Websites, patent fillings, videos etc. (1)

Project presentation prepared, website launched and communication plan developed

Setting up consortium website public and secured intranet Communication plan regulating the consortium communication

Publications

Peer reviewed articles (14)

Human Organotypic Airway and Lung Organoid Cells of Bronchiolar and Alveolar Differentiation Are Permissive to Infection by Influenza and SARS-CoV-2 Respiratory Virus

Auteurs: Camilla Tvedt Ekanger, Fan Zhou, Dana Bohan, Maria Lie Lotsberg, Maria Ramnefjell, Laurence Hoareau, Gro Vatne Røsland, Ning Lu, Marianne Aanerud, Fabian Gärtner, Pirjo Riitta Salminen, Mariann Bent
Publié dans: Frontiers in Cellular and Infection Microbiology, Numéro 12, 2022, Page(s) 841447, ISSN 2235-2988
Éditeur: Frontiers Media S. A.
DOI: 10.3389/fcimb.2022.841447

Seasonal influenza vaccination expands hemagglutinin-specific antibody breadth to older and future A/H3N2 viruses

Auteurs: Nina Urke Ertesvåg, Rebecca Jane Cox, Sarah Larteley Lartey, Kristin G-I Mohn, Karl Albert Brokstad, Mai-Chi Trieu
Publié dans: npj Vaccines, Numéro 7, 2022, Page(s) 490, ISSN 2059-0105
Éditeur: Springer Science and Business Media LLC
DOI: 10.1038/s41541-022-00490-0

Intranasal administration of octavalent next-generation influenza vaccine elicits protective immune responses against seasonal and pre-pandemic viruses

Auteurs: Naoko Uno, Thomas Ebensen, Carlos A. Guzman, Ted M. Ross
Publié dans: Journal of Virology, Numéro 98, 2024, ISSN 0022-538X
Éditeur: American Society for Microbiology
DOI: 10.1128/jvi.00354-24

Effects of repeated influenza vaccination and infection on durable seroprotection in healthcare workers

Auteurs: Mai-Chi Trieu, Amit Bansal, Marianne Sævik, Sonja Ljostveit, Åsne Jul-Larsen, Rebecca Jane Cox
Publié dans: npj Vaccines, Numéro 10, 2025, Page(s) 1259, ISSN 2059-0105
Éditeur: Springer Science and Business Media LLC
DOI: 10.1038/s41541-025-01259-x

Influenza hemagglutinin and neuraminidase multivalent vaccine elicits broader protective immune responses compared to vaccine formulations composed of hemagglutinin or neuraminidase

Auteurs: Naoko Uno, Ted M. Ross
Publié dans: Human Vaccines & Immunotherapeutics, Numéro 21, 2026, Page(s) 259961, ISSN 2164-5515
Éditeur: Landes Bioscience
DOI: 10.1080/21645515.2025.2599611

Repeated Influenza Vaccination Boosts and Maintains H1N1pdm09 Neuraminidase Antibody Titers

Auteurs: Lena Hansen, Fan Zhou, Håkon Amdam, Mai-Chi Trieu, Rebecca Jane Cox
Publié dans: Frontiers in Immunology, Numéro 12, 2021, Page(s) 748264, ISSN 1664-3224
Éditeur: Frontiers Media SA
DOI: 10.3389/fimmu.2021.748264

Impact of Pre-Existing Immunity and Age on Antibody Responses to Live Attenuated Influenza Vaccine

Auteurs: Lukas Hoen, Sarah Lartey, Fan Zhou, Rishi D. Pathirana, Florian Krammer, Kristin G -I Mohn, Rebecca J. Cox, Karl A. Brokstad
Publié dans: Vaccines, Numéro 12, 2025, Page(s) 864, ISSN 2076-393X
Éditeur: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/vaccines12080864

Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection

Auteurs: Fan Zhou, Lena Hansen, Gabriel Pedersen, Gunnveig Grødeland, Rebecca Cox
Publié dans: Frontiers in Immunology, Numéro 12, 2021, Page(s) 747774, ISSN 1664-3224
Éditeur: Frontiers Media SA
DOI: 10.3389/fimmu.2021.747774

Next Generation Influenza Vaccines: Looking into theCrystal Ball

Auteurs: Carlos Alberto Guzmán
Publié dans: Vaccines, 2020, ISSN 2076-393X
Éditeur: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/vaccines8030464

DNA vaccines targeting hemagglutinin from 18 subtypes of influenza A virus to antigen-presenting cells confer broad protection

Auteurs: Ane Marie Anderson, Elias Tjärnhage, Daniëla Maria Hinke, Ranveig Braathen, Gunnveig Grodeland, Bjarne Bogen
Publié dans: Molecular Therapy Nucleic Acids, Numéro 37, 2026, Page(s) 102814, ISSN 2162-2531
Éditeur: Nature Publishing Group
DOI: 10.1016/j.omtn.2025.102814

Point-of-Care Influenza Testing Impacts Clinical Decision, Patient Flow, and Length of Stay in Hospitalized Adults

Auteurs: Elisabeth B Fjelltveit, Rebecca J Cox, Jørgen Østensjø, Bjørn Blomberg, Marit H Ebbesen, Nina Langeland, Kristin G I Mohn
Publié dans: The Journal of Infectious Diseases, Numéro 226, 2022, Page(s) 97-108, ISSN 0022-1899
Éditeur: University of Chicago Press
DOI: 10.1093/infdis/jiaa690

Safety, Immunogenicity, Efficacy and Effectiveness of Inactivated Influenza Vaccines in Healthy Pregnant Women and Children Under 5 Years: An Evidence-Based Clinical Review

Auteurs: Amit Bansal, Mai-Chi Trieu, Kristin G. I. Mohn, Rebecca Jane Cox
Publié dans: Frontiers in Immunology, Numéro 12, 2021, Page(s) 744774, ISSN 1664-3224
Éditeur: Frontiers Media SA
DOI: 10.3389/fimmu.2021.744774

Multivalent next generation influenza virus vaccines protect against seasonal and pre-pandemic viruses

Auteurs: Naoko Uno, Ted M. Ross
Publié dans: Scientific Reports, Numéro 14, 2024, ISSN 2045-2322
Éditeur: Nature Publishing Group
DOI: 10.1038/s41598-023-51024-0

Prospects and Challenges in the Development of Universal Influenza Vaccines

Auteurs: Anders Madsen, Rebecca Jane Cox
Publié dans: Vaccines, Numéro 8, 2025, Page(s) 361, ISSN 2076-393X
Éditeur: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/vaccines8030361